PDCD1 and colorectal cancer: In pre-clinical mouse models of colorectal cancer (MC38 and CT26), the effects of “silent” Fc vs. “competent” Fc on TIM-3 antibody-mediated anti-tumor activity with or without anti-PD-1 antibody treatment were evaluated by several groups (106, 107).